Takeda Pharmaceuticals
Senior Medical Director
Pfizer Sep 2001 - Sep 2008
Senior Medical Director; Therapeutic Area Lead For Oncology, Medical and Scientific Analysis
Rhone-Poulenc Rorer 1995 - 1996
Medical Director
Harvard Medical School Jun 1985 - Jun 1989
Assistant Professor
Education:
Harvard University 1980 - 1985
Skills:
Clinical Research Clinical Trials Pharmaceutical Industry Biotechnology Oncology Drug Development Clinical Development Healthcare Life Sciences Gcp
Alkermes Pharmaceuticals 2018 - Jul 2019
Vice President - Oncology
International Conference on Harmonization Ich E8 Clinical Protocols 2017 - 2018
Expert Working Group - Modernization Initiative
Takeda Pharmaceuticals 2017 - 2018
Head, Oncology Development and Scientific Initiatives
Fda Oncology Drugs Advisory Committee 2013 - 2016
Industry Representative
Pfizer Sep 2002 - Sep 2008
Senior Medical Director
Education:
Brandeis University 1968 - 1973
Masters, Master of Arts, Bachelors, Bachelor of Arts, Premed
Harvard Medical School
Skills:
Biotechnology Clinical Development Immunology Clinical Trials Oncology Medical Affairs Life Sciences Pharmaceutical Industry Clinical Research U.s. Food and Drug Administration
Interests:
Children Civil Rights and Social Action Environment Education Science and Technology Human Rights Arts and Culture Health
Howard Fingert - New London CT, US Robert Klem - Rancho Santa Fe CA, US
Assignee:
Genta Incorporated - Berkeley Heights NJ
International Classification:
A61K 31/7088 A61P 35/00
US Classification:
514 44 A
Abstract:
The present invention is directed to the use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders. These disorders include cancers, tumors, carcinomas and cell-proliferative related disorders. In one embodiment of the invention, a bcl-2 antisense oligomer is administered at high doses. The present invention is also directed to a method of preventing or treating a bcl-2 related disorder, in particular cancer, comprising administering a bcl-2 antisense oligomer for short periods of time. The present invention is further drawn to the use of bcl-2 antisense oligomers to increase the sensitivity of a subject to cancer therapeutics. The present invention also relates to pharmaceutical compositions comprising one or more bcl-2 antisense oligomers, which may comprise one or more cancer therapeutic agents.
Medicine Doctors
Dr. Howard Fingert, Chestnut Hill MA - MD (Doctor of Medicine)
115 Waban Hill Rd N, Chestnut Hill, MA 02467 8607322776 (Phone)
Certifications:
Hematology, 1982 Internal Medicine, 1980 Medical Oncology, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School University of Illinois At Chicago / College of Medicine Graduated: 1977 Medical School Cedars-Sinai Medical Center Graduated: 1977 Medical School Harvard University Graduated: 1977